Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Chromadex Corp CS (NQ: CDXC ) 3.250 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 3.250 Bid (Size) 2.800 (5) Ask (Size) 3.380 (5) Prev. Close 3.250 Today's Range 3.250 - 3.250 52wk Range 1.250 - 4.650 Shares Outstanding 68,196,526 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 May 23, 2024 From ChromaDex Corporation Via Business Wire ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award May 22, 2024 From ChromaDex Corporation Via Business Wire Performance YTD +127.27% +127.27% 1 Month -4.41% -4.41% 3 Month +113.82% +113.82% 6 Month +112.42% +112.42% 1 Year +116.67% +116.67% More News Read More CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023 March 06, 2024 Via InvestorPlace Earnings Preview For ChromaDex March 05, 2024 Via Benzinga ChromaDex: Q3 Earnings Insights November 08, 2023 Via Benzinga Earnings Outlook For ChromaDex November 07, 2023 Via Benzinga CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's After-Market Session May 08, 2024 Via Benzinga ChromaDex Corporation Reports First Quarter 2024 Financial Results May 08, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® April 25, 2024 From ChromaDex Corporation Via Business Wire ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement April 30, 2024 From ChromaDex Corporation Via Business Wire ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 April 24, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market April 23, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program March 26, 2024 From ChromaDex Corporation Via Business Wire 12 Health Care Stocks Moving In Monday's Intraday Session March 18, 2024 Via Benzinga ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results March 06, 2024 From ChromaDex Corporation Via Business Wire ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 February 21, 2024 From ChromaDex Corporation Via Business Wire Earnings Scheduled For March 6, 2024 March 06, 2024 Via Benzinga ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 February 05, 2024 From ChromaDex Corporation Via Business Wire ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference January 26, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® December 20, 2023 From ChromaDex Corporation Via Business Wire A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) November 30, 2023 From ChromaDex Corporation Via Business Wire ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023 November 09, 2023 From ChromaDex Corporation Via Business Wire ChromaDex Corporation Reports Third Quarter 2023 Financial Results November 08, 2023 From ChromaDex Corporation Via Business Wire Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients November 15, 2023 From ChromaDex Corporation Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
